IMV (TSE:IMV) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.
Profitability
This table compares IMV and Burcon NutraScience's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
IMV | N/A | N/A | N/A |
Burcon NutraScience | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for IMV and Burcon NutraScience, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
IMV | 0 | 4 | 0 | 0 | 2.00 |
Burcon NutraScience | 0 | 0 | 1 | 0 | 3.00 |
IMV presently has a consensus target price of C$5.08, suggesting a potential upside of 49.95%. Burcon NutraScience has a consensus target price of C$5.00, suggesting a potential downside of 1.19%. Given IMV's higher probable upside, research analysts plainly believe IMV is more favorable than Burcon NutraScience.
Valuation and Earnings
This table compares IMV and Burcon NutraScience's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
IMV | C$3,000.00 | 76,513.43 | C$-39,136,958.00 | C($0.58) | -5.87 |
Burcon NutraScience | C$12,045.00 | 44,992.20 | C$107,101.00 | C$0.00 | 5,060.00 |
Burcon NutraScience has higher revenue and earnings than IMV. IMV is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.
Summary
Burcon NutraScience beats IMV on 6 of the 8 factors compared between the two stocks.